USO 25044
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer
Disease Types: Genitourinary Cancer Research
Eligibility Requirements:
• Subjects must have histological, pathological, and/or cytological confirmation
of adenocarcinoma of the prostate
• mCRPC with ≥ 1 metastatic lesion that is present on baseline CT, MRI, or
bone scan imaging
• Subjects must have had prior orchiectomy and/or ongoing ADT and a castrate
level of serum testosterone
• Subjects must have prior disease progression on only 1 ARPI
• Subjects intended to receive cabazitaxel must have previously received ≤ 6
cycles of docetaxel in the mHSPC setting.
• Subjects with prior disease progression on or intolerance to abiraterone are
excluded
• Subjects that received prior STEAP1-targeted therapy are excluded
For more information on this trial CLICK HERE .
Available at: